CTOs on the Move

True North Consulting

www.truenorthconsult.com

 
True North Consulting is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Prime Medica

Prime Medica is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paradigm Health Plans

Paradigm Health Plans is the industry leader in creating self-funded value-based benefit designs for a total solution for your workforce. Founded in 2007, Paradigm has been partnering with businesses nationally to empower employers and their workforce to actively manage their healthcare costs.

Bridgemedica

Bridgemedica is a Walpole, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jewish Hospital and St. Mary's HealthCare, Inc.

Jewish Hospital and St. Mary's HealthCare, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Louisville, KY. To find more information about Jewish Hospital and St. Mary's HealthCare, Inc., please visit www.jhsmh.org

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.